Millipore has acquired BioAnaLab, a European-based services provider that specializes in the analysis of biologic drugs and vaccines. The transaction enables Millipore to expand its biopharma services business into Europe

"Our acquisition of BioAnaLab will allow us to build on our reputation as a trusted outsource partner in North America by establishing a presence in the fast-growing European biotech market," said Jonathan DiVincenzo, president of Millipore's Bioscience Division. "BioAnaLab will add cGMP support testing capabilities to our portfolio, a solid customer base, and a team of highly talented services professionals with expertise in emerging scientific disciplines."

Based in Oxford, UK, BioAnaLab was spun out of the University of Oxford in 2002 to meet the unique requirements of the biopharmaceutical industry by helping its customers better understand the safety and efficacy of biologic drugs and vaccines, using "a broad range of services to assist with evaluating and advancing these therapeutics from the drug development pipeline to the market," according to a Millipore statement. BioAnaLab's services include assay transfer/development, validation and sample analysis, pharmacokinetics/toxicokinetics, immunogenicity, biological potency, and vaccine services.

Sign up today for Contracting & Outsourcing 2009!

News from our sister sites